Review

cd89 humanized mice (Shanghai Model Organisms Center)

Name: cd89 humanized mice
Brand: Shanghai Model Organisms Center
Rating: 90 (1 reviews)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

Shanghai Model Organisms Center cd89 humanized mice
Cd89 Humanized Mice, supplied by Shanghai Model Organisms Center, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd89 humanized mice/product/Shanghai Model Organisms Center
Average 90 stars, based on 1 article reviews

cd89 humanized mice - by Bioz Stars, 2026-03

90/100 stars

Images

Image Search Results

Mouse-Ly-6G efficiently depleted neutrophils in C57Bl6/J, Balb/c, NXG, and SCID mice. ( a ) Experimental set-up; i.p. injections with the depletion antibodies were performed three times a week for four weeks. Blood was drawn via cheek puncture once a week before injection with the antibodies; ( b , c ) Longitudinal analysis of the number of CD45 + Siglec-F − CD115 − SSC high Gr-1 + CD11b + neutrophils in the peripheral blood ( n = five mice per group) per 5000 latex beads, showing; ( b ) Significant, almost complete, neutrophil depletion in all mouse strains tested (C57Bl6/J, Balb/c, NXG, and SCID) upon treatment with 100 μg mouse-Ly-6G antibody, and ( c ) Significantly better neutrophil depletion in 100 μg mouse-Ly-6G treated C57Bl6/J mice than when treated with 100 μg rat-Ly-6G antibody. Data is presented as mean with SEM. Statistics: one-way ANOVA with Bonferroni correction. Repeated measures one-way ANOVA with Bonferroni correction was used to compare groups in c, * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.

Journal: Cells

Article Title: Effective, Long-Term, Neutrophil Depletion Using a Murinized Anti-Ly-6G 1A8 Antibody

doi: 10.3390/cells11213406

Figure Lengend Snippet: Mouse-Ly-6G efficiently depleted neutrophils in C57Bl6/J, Balb/c, NXG, and SCID mice. ( a ) Experimental set-up; i.p. injections with the depletion antibodies were performed three times a week for four weeks. Blood was drawn via cheek puncture once a week before injection with the antibodies; ( b , c ) Longitudinal analysis of the number of CD45 + Siglec-F − CD115 − SSC high Gr-1 + CD11b + neutrophils in the peripheral blood ( n = five mice per group) per 5000 latex beads, showing; ( b ) Significant, almost complete, neutrophil depletion in all mouse strains tested (C57Bl6/J, Balb/c, NXG, and SCID) upon treatment with 100 μg mouse-Ly-6G antibody, and ( c ) Significantly better neutrophil depletion in 100 μg mouse-Ly-6G treated C57Bl6/J mice than when treated with 100 μg rat-Ly-6G antibody. Data is presented as mean with SEM. Statistics: one-way ANOVA with Bonferroni correction. Repeated measures one-way ANOVA with Bonferroni correction was used to compare groups in c, * = p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.

Article Snippet: Experiments were conducted using C57Bl/6J (C57Bl/6JRj), Balb/c (Balb/cByJRj), NXG (NOD.Prkdc scid Il2rg tm1 /Rj), SCID (NOD.CB17-Prkdc scid/scid /Rj), and human FcαRI (CD89) transgenic SCID mice (all housed and bred at Janvier Labs, Paris, France) [ ], or C57Bl/6J FcRγ −/− (C57Bl/6JRj FcRγ-chain knockout) mice (housed and bred at the University of Utrecht) [ ].

Techniques: Injection

Mouse-Ly-6G efficiently depletes neutrophils in the blood and tumor of IMR32 tumor-bearing SCID mice ( a ) Experimental set-up; 2.5 × 10 6 IMR32 cells were s.c. injected in SCID mice in a 1:2 mix with Vitrogel Hydrogel Matrix. Tumors were established for 28 days, after which mice were randomized over the different treatment groups, and treatment was started. I.p. injections with PBS, IgA ch14.18, and mouse-Ly-6G were performed three times a week for six weeks. The SIRPα-D1 fusion protein was injected i.p. every nine days. Blood was drawn via cheek puncture once a week before injection with the antibodies; ( b ) Longitudinal analysis of the percentage of SSC high Ly-6C low Ly-6G + CD11b + neutrophils in the peripheral blood ( n = 2–5 mice per group) of the CD45+ leukocyte population, showing complete neutrophil depletion upon treatment with 100 μg mouse-Ly-6G antibody. Of note; blood at day 70 was collected from the orbit and processed in a similar fashion as the tumor material, meaning cells were fixed at a later time point, possibly resulting in some neutrophil cell death; ( c ) Intratumoral analysis of the percentage of SSC high Ly-6C low Ly-6G + CD11b + neutrophils of the live (TO-PRO-3 negative) cells, CD45+ leukocytes, and CD11b+ myeloid populations. Data showed increased tumor infiltration when the mice were treated with IgA ch14.18/SIRPα-D1 fusion, which was completely ablated when 100 μg mouse Ly-6G was added. Data is presented as mean with SEM. Statistics: one-way ANOVA with Bonferroni correction. Repeated measures one-way ANOVA with Bonferroni correction was used to compare groups in b, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.

Journal: Cells

Article Title: Effective, Long-Term, Neutrophil Depletion Using a Murinized Anti-Ly-6G 1A8 Antibody

doi: 10.3390/cells11213406

Figure Lengend Snippet: Mouse-Ly-6G efficiently depletes neutrophils in the blood and tumor of IMR32 tumor-bearing SCID mice ( a ) Experimental set-up; 2.5 × 10 6 IMR32 cells were s.c. injected in SCID mice in a 1:2 mix with Vitrogel Hydrogel Matrix. Tumors were established for 28 days, after which mice were randomized over the different treatment groups, and treatment was started. I.p. injections with PBS, IgA ch14.18, and mouse-Ly-6G were performed three times a week for six weeks. The SIRPα-D1 fusion protein was injected i.p. every nine days. Blood was drawn via cheek puncture once a week before injection with the antibodies; ( b ) Longitudinal analysis of the percentage of SSC high Ly-6C low Ly-6G + CD11b + neutrophils in the peripheral blood ( n = 2–5 mice per group) of the CD45+ leukocyte population, showing complete neutrophil depletion upon treatment with 100 μg mouse-Ly-6G antibody. Of note; blood at day 70 was collected from the orbit and processed in a similar fashion as the tumor material, meaning cells were fixed at a later time point, possibly resulting in some neutrophil cell death; ( c ) Intratumoral analysis of the percentage of SSC high Ly-6C low Ly-6G + CD11b + neutrophils of the live (TO-PRO-3 negative) cells, CD45+ leukocytes, and CD11b+ myeloid populations. Data showed increased tumor infiltration when the mice were treated with IgA ch14.18/SIRPα-D1 fusion, which was completely ablated when 100 μg mouse Ly-6G was added. Data is presented as mean with SEM. Statistics: one-way ANOVA with Bonferroni correction. Repeated measures one-way ANOVA with Bonferroni correction was used to compare groups in b, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001.

Techniques: Injection

Design and validation of X-body and square-body. A) Schematic diagram of the heavy chain and light chain-IgA Fc chimeric chains of the X-body. B) Schematic of X-body. C) Schematic diagram of the two heavy chains and two chimeric chains to assembly the square body. D) Assembly of square body. The N-terminal-and C-terminal domains of each chain were labeled as N and C, respectively. Electron microscopy images of the X-body (E) and square body (F) . Through 2D class averaging, 9102 X-body particles ( E ) or 4873 square-body particles ( F ) were sorted into 15 classes. The binding of rituximab X-body to antigen CD20 (G) and Fc receptors, such as CD89 (H) , FcRn (I) , FcγRI (J) , FcγRIIa H131 (K) , and FcγRIIIa F158 (L) , as evaluated by SPR.

Journal: Theranostics

Article Title: Self-assembly of X-shaped antibody to combine the activity of IgG and IgA for enhanced tumor killing

doi: 10.7150/thno.74903

Figure Lengend Snippet: Design and validation of X-body and square-body. A) Schematic diagram of the heavy chain and light chain-IgA Fc chimeric chains of the X-body. B) Schematic of X-body. C) Schematic diagram of the two heavy chains and two chimeric chains to assembly the square body. D) Assembly of square body. The N-terminal-and C-terminal domains of each chain were labeled as N and C, respectively. Electron microscopy images of the X-body (E) and square body (F) . Through 2D class averaging, 9102 X-body particles ( E ) or 4873 square-body particles ( F ) were sorted into 15 classes. The binding of rituximab X-body to antigen CD20 (G) and Fc receptors, such as CD89 (H) , FcRn (I) , FcγRI (J) , FcγRIIa H131 (K) , and FcγRIIIa F158 (L) , as evaluated by SPR.

Article Snippet: Human CD89 transgenic mice (cat # NM-KI-200063) and human FcRn transgenic mice (cat # NM-HU-00109) were purchased from the Shanghai Model Organisms Center, Inc. Human CD89 transgenic mice express CD89 under the CD11b promoter.

Techniques: Biomarker Discovery, Labeling, Electron Microscopy, Binding Assay

The anticancer efficacy of rituximab X-body in the Eg7 syngeneic murine model. A) Schematic of the treatment regimen. Eg7-hCD20-Luc tumor cells were intraperitoneally inoculated into human CD89 transgenic mice. The mice were treated with different forms of rituximab antibody. B) Bioluminescence imaging (BLI) of Eg7-hCD20-Luc tumor cells before treatment (Day2) and 24 hours after treatment (Day3). C-D) Quantification of bioluminescence signal and inhibition of cancer cells by the treatment was calculated. * p ≤ 0.05. E-L) Proportion and activation status of infiltrating immune cells in ascites of tumor-bearing mice. Cells were isolated from mouse ascites, stained with the indicated antibodies and analyzed by flow cytometry. The percentages of NK cells (E), neutrophils (G) and Macrophages (I) and the activation status of NK cells (F), neutrophils (H), and macrophages (J-L) were analyzed. Data are presented as mean ± standard error of the mean (SEM). * p ≤ 0.05.

Journal: Theranostics

Article Title: Self-assembly of X-shaped antibody to combine the activity of IgG and IgA for enhanced tumor killing

doi: 10.7150/thno.74903

Figure Lengend Snippet: The anticancer efficacy of rituximab X-body in the Eg7 syngeneic murine model. A) Schematic of the treatment regimen. Eg7-hCD20-Luc tumor cells were intraperitoneally inoculated into human CD89 transgenic mice. The mice were treated with different forms of rituximab antibody. B) Bioluminescence imaging (BLI) of Eg7-hCD20-Luc tumor cells before treatment (Day2) and 24 hours after treatment (Day3). C-D) Quantification of bioluminescence signal and inhibition of cancer cells by the treatment was calculated. * p ≤ 0.05. E-L) Proportion and activation status of infiltrating immune cells in ascites of tumor-bearing mice. Cells were isolated from mouse ascites, stained with the indicated antibodies and analyzed by flow cytometry. The percentages of NK cells (E), neutrophils (G) and Macrophages (I) and the activation status of NK cells (F), neutrophils (H), and macrophages (J-L) were analyzed. Data are presented as mean ± standard error of the mean (SEM). * p ≤ 0.05.

Techniques: Transgenic Assay, Imaging, Inhibition, Activation Assay, Isolation, Staining, Flow Cytometry

The equilibrium constants of Trastuzumab antibodies

Journal: Theranostics

Article Title: Self-assembly of X-shaped antibody to combine the activity of IgG and IgA for enhanced tumor killing

doi: 10.7150/thno.74903

Figure Lengend Snippet: The equilibrium constants of Trastuzumab antibodies

Techniques:

Tumor inhibition efficacy of trastuzumab X-body in colon cancer syngeneic mouse model. A) Schematic of the treatment regimen. MC38-HER2 cancer cells were subcutaneously implanted in human CD89 transgenic mice. When tumor reached 30-50 mm 3 , the mice were treated with different version of trastuzumab at the indicated time points. B) Tumor growth of mice treated with PBS, trastuzumab X-body, IgG or IgA. C) Kaplan-Meier survival curves of tumor-bearing mice. D-K) Flow cytometry analysis of the tumor-infiltrating immune cells. Tumor immune cells were isolated three days after 5 doses of drugs, stained with indicated antibodies and analyzed by flow cytometry. The percentages of NK cells (D), neutrophils (F), and macrophages (H) and the activation status of NK cells (E), neutrophils (G), and macrophages (I-K) were analyzed. Data are presented as mean ± standard error of the mean (SEM). ** p ≤ 0.01, * p ≤ 0.05.

Journal: Theranostics

Article Title: Self-assembly of X-shaped antibody to combine the activity of IgG and IgA for enhanced tumor killing

doi: 10.7150/thno.74903

Figure Lengend Snippet: Tumor inhibition efficacy of trastuzumab X-body in colon cancer syngeneic mouse model. A) Schematic of the treatment regimen. MC38-HER2 cancer cells were subcutaneously implanted in human CD89 transgenic mice. When tumor reached 30-50 mm 3 , the mice were treated with different version of trastuzumab at the indicated time points. B) Tumor growth of mice treated with PBS, trastuzumab X-body, IgG or IgA. C) Kaplan-Meier survival curves of tumor-bearing mice. D-K) Flow cytometry analysis of the tumor-infiltrating immune cells. Tumor immune cells were isolated three days after 5 doses of drugs, stained with indicated antibodies and analyzed by flow cytometry. The percentages of NK cells (D), neutrophils (F), and macrophages (H) and the activation status of NK cells (E), neutrophils (G), and macrophages (I-K) were analyzed. Data are presented as mean ± standard error of the mean (SEM). ** p ≤ 0.01, * p ≤ 0.05.

Techniques: Inhibition, Transgenic Assay, Flow Cytometry, Isolation, Staining, Activation Assay

Tumor inhibition efficacy of trastuzumab X-body in bladder cancer syngeneic mouse model. A) Schematic of the treatment regimen. MB49-HER2 cancer cells were subcutaneously implanted in human CD89 transgenic mice. B) Tumor growth of mice treated with PBS, trastuzumab X-body, IgG or IgA. C) Kaplan-Meier survival curves of tumor-bearing mice. D-K) Flow cytometry analysis of the tumor-infiltrating immune cells. Tumor immune cells were isolated three days after 5 doses of drugs, stained with indicated antibodies and analyzed by flow cytometry. Proportion of tumor-infiltrating immune cells in live cells (D), the proportion of NK cells (E), neutrophils (G), and macrophages (I) in total tumor-infiltrating immune cells and the activation status of NK cells (F), neutrophils (H), and macrophages (J and K) were analyzed. Data are presented as mean ± standard error of the mean (SEM). ** p ≤ 0.01, * p ≤ 0.05.

Journal: Theranostics

Article Title: Self-assembly of X-shaped antibody to combine the activity of IgG and IgA for enhanced tumor killing

doi: 10.7150/thno.74903

Figure Lengend Snippet: Tumor inhibition efficacy of trastuzumab X-body in bladder cancer syngeneic mouse model. A) Schematic of the treatment regimen. MB49-HER2 cancer cells were subcutaneously implanted in human CD89 transgenic mice. B) Tumor growth of mice treated with PBS, trastuzumab X-body, IgG or IgA. C) Kaplan-Meier survival curves of tumor-bearing mice. D-K) Flow cytometry analysis of the tumor-infiltrating immune cells. Tumor immune cells were isolated three days after 5 doses of drugs, stained with indicated antibodies and analyzed by flow cytometry. Proportion of tumor-infiltrating immune cells in live cells (D), the proportion of NK cells (E), neutrophils (G), and macrophages (I) in total tumor-infiltrating immune cells and the activation status of NK cells (F), neutrophils (H), and macrophages (J and K) were analyzed. Data are presented as mean ± standard error of the mean (SEM). ** p ≤ 0.01, * p ≤ 0.05.

Techniques: Inhibition, Transgenic Assay, Flow Cytometry, Isolation, Staining, Activation Assay

Analysis of tumor-infiltrating immune cells by single-cell RNA sequencing. A) Tumor infiltrating immune cells were isolated and subjected to single-cell RNA sequencing. The t-SNE plot showed the immune cells by scRNA-seq. B) Proportion of immune cells of different clusters in the total immune cells. C-D) Heatmap showing expression of genes in the selected pathways for NK cells (C) and neutrophils (D). E) t-SNE plot showing expression levels of selected genes defining M1/M2 phenotype of tumor-associated macrophages. F) Schematic of the treatment regimen of single drugs or the combination of drugs. MB49-HER2 cancer cells were subcutaneously implanted in human CD89 transgenic mice and the mice were treated by intraperitoneal injection of single drug such as PBS, trastuzumab X-body,TLR7/8 agonist or the combination of these drugs for 5 times. G) Tumor growth of mice treated with PBS, trastuzumab X-body,TLR7/8 agonist or the combination of the drugs. H) Kaplan-Meier survival curves of tumor-bearing mice. Data are presented as mean ± SEM. ** p ≤ 0.01, * p ≤ 0.05.

Journal: Theranostics

Article Title: Self-assembly of X-shaped antibody to combine the activity of IgG and IgA for enhanced tumor killing

doi: 10.7150/thno.74903

Figure Lengend Snippet: Analysis of tumor-infiltrating immune cells by single-cell RNA sequencing. A) Tumor infiltrating immune cells were isolated and subjected to single-cell RNA sequencing. The t-SNE plot showed the immune cells by scRNA-seq. B) Proportion of immune cells of different clusters in the total immune cells. C-D) Heatmap showing expression of genes in the selected pathways for NK cells (C) and neutrophils (D). E) t-SNE plot showing expression levels of selected genes defining M1/M2 phenotype of tumor-associated macrophages. F) Schematic of the treatment regimen of single drugs or the combination of drugs. MB49-HER2 cancer cells were subcutaneously implanted in human CD89 transgenic mice and the mice were treated by intraperitoneal injection of single drug such as PBS, trastuzumab X-body,TLR7/8 agonist or the combination of these drugs for 5 times. G) Tumor growth of mice treated with PBS, trastuzumab X-body,TLR7/8 agonist or the combination of the drugs. H) Kaplan-Meier survival curves of tumor-bearing mice. Data are presented as mean ± SEM. ** p ≤ 0.01, * p ≤ 0.05.

Techniques: RNA Sequencing, Isolation, Expressing, Transgenic Assay, Injection

Journal: Theranostics

Article Title: Self-assembly of X-shaped antibody to combine the activity of IgG and IgA for enhanced tumor killing

doi: 10.7150/thno.74903

Figure Lengend Snippet: Evaluation of toxicology and pharmacokinetics of X-body in mice. A-D) Blood was collected three days after the last treatment and ALT (A), AST (B), CR (C) and UA (D) levels were analyzed. E, F) H&E staining of liver and kidney from MB49-HER2 tumor-bearing mice three days after the last treatment. G) Changes in body weight of MB49-HER2 tumor-bearing mice under different treatments. H) Pharmacokinetic profile. The hFcRn transgenic mice were injected with a single dose of antibody. Blood samples were collected at the indicated times. Serum levels for antibodies in mice were quantified by ELISA. The pharmacokinetic parameters were calculated by WinNonlin software.

Techniques: Drug discovery, Staining, Transgenic Assay, Injection, Enzyme-linked Immunosorbent Assay, Software

Review

Structured Review

Images

Similar Products

Image Search Results